These findings underscore the therapeutic potential of Cdk5 inhibitors, particularly BLINK11, in ameliorating cognitive deficits associated with T2D conditions induced by an HFD, providing valuable insights for future research and potential clinical applications. The gene discussed is CDK5; the disease is type 2 diabetes mellitus.